Aspirin-d
Cat. No.：YN280161
| 产品名称: | Aspirin-d |
| CAS No.: | 1126721-82-1 |
| Chemical Name: | N-[2-[di(ethyl-1,1,2,2,2-d5)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| Synonyms: | SU 11248-d |
| 分子量: | 408.5 |
| 分子式: | C22H17D10FN4O2 |
| SMILES: | CC1=C(/C=C2C(NC3=C\2C=C(F)C=C3)=O)NC(C)=C1C(NCCN(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H])=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Sunitinib-d10是 Sunitinib 的氘代物。Sunitinib 是一种多靶点受体酪氨酸激酶抑制剂，抑制VEGFR2和PDGFRβ的IC50分别为 80 nM 和 2 nM。Sunitinib 是ATP 竞争性抑制剂，可通过抑制自身磷酸化和随后的 RNase 激活来有效抑制Ire1α的磷酸化。 |
| IC50和靶点: | [{name:"VEGFR2:80 nM (IC50)"},{name: "PDGFRβ:2 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
O'Farrell, A.M., Abrams, T.J., Yuen, H.A., et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood101(9),3597-3605(2003)
Mendel, D.B., Laird, A.D., Xin, X., et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationshipClin. Cancer Res.9(1),327-337(2003)
